Scientists have been trying to identify every gene in the human genome since the initial draft
was published in 2001. In the years since, much progress has been made in identifying …

Over the past 15 years, rapid progress has been made in developmental therapeutics,
especially regarding the use of matched targeted therapies against specific oncogenic …

There is a growing need for systems that efficiently support the work of medical teams at the
precision-oncology point of care. Here, we present the implementation of the Molecular …

Since June 2019, under the umbrella of the national health insurance system, Japan has
started cancer genomic medicine (CGM) with comprehensive genomic profiling (CGP) tests …

The promising expectations about personalized medicine have opened the path to routine
large-scale sequencing and increased the importance of genetic counseling for hereditary …

Reversion mutations in BRCA1 or BRCA2 are associated with resistance to PARP inhibitors
and platinum. To better understand the nature of these mutations, we collated, codified, and …

Estimating the effects of variants found in disease driver genes opens the door to
personalized therapeutic opportunities. Clinical associations and laboratory experiments …

The unknown pathogenicity of a significant number of variants found in cancer-related
genes is attributed to limited epidemiological data, resulting in their classification as variant …

To the Editor—The optimal management of patients with cancer is increasingly dependent
on individualized treatments guided by tumor sequencing data. As comprehensive genomic …

The inheritance of monoallelic germline mutations affecting BRCA1 or BRCA2 predisposes
with a high penetrance to several forms of epithelial malignancy. The large, nuclear …